84 related articles for article (PubMed ID: 9545823)
1. [Prospects for gene therapy for chronic granulomatous disease with gp91-phox deficiency].
Nunoi H; Sugimoto Y; Kanegasaki S
Rinsho Ketsueki; 1998 Feb; 39(2):132. PubMed ID: 9545823
[No Abstract] [Full Text] [Related]
2. Chronic granulomatous disease: towards gene therapy.
Thrasher A; Segal A; Casimir C
Immunodeficiency; 1993; 4(1-4):327-33. PubMed ID: 8167728
[TBL] [Abstract][Full Text] [Related]
3. [Statistical evaluation of chronic granulomatous disease in Japan and basic studies for gene therapy for CGD patients].
Nunoi H; Ishibashi F
Rinsho Byori; 1999 Jul; 47(7):658-64. PubMed ID: 10442045
[TBL] [Abstract][Full Text] [Related]
4. Progress toward effective gene therapy for chronic granulomatous disease.
Malech HL; Choi U; Brenner S
Jpn J Infect Dis; 2004 Oct; 57(5):S27-8. PubMed ID: 15507764
[TBL] [Abstract][Full Text] [Related]
5. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
6. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.
Zentilin L; Tafuro S; Serra C; Falaschi A; Giacca M
Ann Ist Super Sanita; 1998; 34(4):447-55. PubMed ID: 10234875
[TBL] [Abstract][Full Text] [Related]
8. [Chronic granulomatous disease].
Iwata M; Nunoi H
Ryoikibetsu Shokogun Shirizu; 2000; (32):179-82. PubMed ID: 11212682
[No Abstract] [Full Text] [Related]
9. The expression of full length Gp91-phox protein is associated with reduced amphotropic retroviral production.
Bellantuono I; Lashford LS; Rafferty JA; Fairbairn LJ
Haematologica; 2000 May; 85(5):451-7. PubMed ID: 10800158
[TBL] [Abstract][Full Text] [Related]
10. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.
Rappa G; Anzanello F; Alexeyev M; Fodstad O; Lorico A
Eur J Haematol; 2007 May; 78(5):440-8. PubMed ID: 17331133
[TBL] [Abstract][Full Text] [Related]
11. Progress in gene therapy for chronic granulomatous disease.
Malech HL
J Infect Dis; 1999 Mar; 179 Suppl 2():S318-25. PubMed ID: 10081502
[TBL] [Abstract][Full Text] [Related]
12. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
13. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract][Full Text] [Related]
14. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.
Barde I; Laurenti E; Verp S; Wiznerowicz M; Offner S; Viornery A; Galy A; Trumpp A; Trono D
Gene Ther; 2011 Nov; 18(11):1087-97. PubMed ID: 21544095
[TBL] [Abstract][Full Text] [Related]
15. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.
Moreno-Carranza B; Gentsch M; Stein S; Schambach A; Santilli G; Rudolf E; Ryser MF; Haria S; Thrasher AJ; Baum C; Brenner S; Grez M
Gene Ther; 2009 Jan; 16(1):111-8. PubMed ID: 18784749
[TBL] [Abstract][Full Text] [Related]
16. Virulence of catalase-deficient aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease.
Chang YC; Segal BH; Holland SM; Miller GF; Kwon-Chung KJ
J Clin Invest; 1998 May; 101(9):1843-50. PubMed ID: 9576747
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for chronic granulomatous disease.
Kume A; Dinauer MC
J Lab Clin Med; 2000 Feb; 135(2):122-8. PubMed ID: 10695656
[TBL] [Abstract][Full Text] [Related]
18. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
Condino-Neto A; Newburger PE
Arch Biochem Biophys; 1998 Dec; 360(2):158-64. PubMed ID: 9851826
[TBL] [Abstract][Full Text] [Related]
19. Genetic and biochemical background of chronic granulomatous disease.
Jurkowska M; Bernatowska E; Bal J
Arch Immunol Ther Exp (Warsz); 2004; 52(2):113-20. PubMed ID: 15179325
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for chronic granulomatous disease.
Stein S; Siler U; Ott MG; Seger R; Grez M
Curr Opin Mol Ther; 2006 Oct; 8(5):415-22. PubMed ID: 17078383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
